A novel in vitro model system for studying the action of ara-C

被引:12
|
作者
Hickey, R
Ross, D
Ross, D
Cuddy, D
Malkas, L
机构
[1] UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201
[2] UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201
[3] UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201
[4] BALTIMORE VET MED CTR,BALTIMORE,MD
[5] UNIV MARYLAND,CTR CANC,DIV DEV THERAPEUT,BALTIMORE,MD 21201
[6] UNIV BALTIMORE,MOLEC & CELLULAR BIOL PROGRAM,BALTIMORE,MD 21201
关键词
cytosine arabinoside; anticancer drugs; mammalian cells; multiprotein DNA replication complex; in vitro model system;
D O I
10.1007/s002800050496
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this report we describe the development of an in vitro model system to study the molecular mechanism of ara-CMP incorporation into DNA. This model system makes use of a recently described human cell multiprotein DNA replication complex (MRC) that is competent to replicate DNA in vitro. The MRC can successfully incorporate ara-CMP into replicating DNA at internucleotide positions. These results are similar to those described for studies using intact cells. This MRC-driven in vitro replication system may therefore serve as a powerful model for the study of anticancer agents that directly affect human cell DNA synthesis.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 50 条
  • [41] MORE ON LOW-DOSE ARA-C
    BERNARDESCHI, P
    BONECHI, I
    HAEMATOLOGICA, 1986, 71 (01) : 86 - 86
  • [42] ARA-C CONJUGATES OF ETHER AND THIOETHER PHOSPHOLIPIDS
    HONG, CI
    WEST, CR
    BERNACKI, RJ
    BERDEL, WE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 359 - 359
  • [43] HIGH-DOSE ARA-C - A SUMMARY
    SEEBER, S
    ONKOLOGIE, 1985, 8 (01): : 57 - 58
  • [44] MECHANISM OF RESISTANCE TO ARA-C IN A MUTANT HERPESVIRUS
    SCHNIPPER, L
    CRUMPACKER, C
    ANTMAN, K
    KUFE, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 220 - 220
  • [45] Transient Ara-c leukoencephalopathy: MR findings
    Patel, AG
    Rao, R
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1996, 20 (01) : 161 - 162
  • [46] ARA-C SCHEDULING - THEORETICAL AND EXPERIMENTAL CONSIDERATIONS
    GRAY, JW
    PALLAVICINI, MG
    MEDICAL AND PEDIATRIC ONCOLOGY, 1982, : 93 - 108
  • [47] THE ARA-C SYNDROME - DIRECT ENDOTHELIAL CYTOTOXICITY
    BOOGAERTS, MA
    MALBRAIN, S
    VERWILGHEN, RL
    BRITISH JOURNAL OF HAEMATOLOGY, 1987, 66 (03) : 423 - 423
  • [48] CLINICAL-PHARMACOLOGY OF INTERMEDIATE DOSE ARA-C (ID ARA-C) IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA IN RELAPSE
    VANPROOYEN, HC
    DEKKER, AW
    PUNT, K
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 60 (02) : 355 - 356
  • [49] GENOTOXIC EVALUATION OF ARA-C BY MULTIPLE PARAMETERS
    HELEN, KDB
    SUBRAMANYAM, S
    MUTATION RESEARCH, 1991, 263 (03): : 185 - 196
  • [50] miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis
    Haitao Bai
    Zhongwei Cao
    Chong Deng
    Lili Zhou
    Chun Wang
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 595 - 602